$23.80
18.94% today
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US15117B1035
Symbol
CLDX

Celldex Therapeutics, Inc. Stock price

$23.80
+0.44 1.88% 1M
+1.54 6.92% 6M
-1.47 5.82% YTD
-9.66 28.87% 1Y
-13.53 36.24% 3Y
+13.60 133.33% 5Y
-225.35 90.45% 10Y
+4.30 22.05% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+3.79 18.94%
ISIN
US15117B1035
Symbol
CLDX
Industry

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$655.5m
Net debt
positive
Cash
$673.3m
Shares outstanding
66.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
175.8 | 364.6
EV/Sales
86.7 | 179.8
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
94.3%
Return on Equity
-21.1%
ROCE
-30.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$7.6m | $3.6m
EBITDA
$-213.9m | $-254.8m
EBIT
$-217.2m | $-258.1m
Net Income
$-178.9m | $-233.8m
Free Cash Flow
$-173.4m
Growth (TTM | estimate)
Revenue
24.3% | -48.1%
EBITDA
-34.0% | -32.8%
EBIT
-33.5% | -32.3%
Net Income
-23.5% | -48.1%
Free Cash Flow
-43.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,830.3% | -6,990.9%
EBIT
-2,873.5%
Net
-2,366.1% | -6,413.2%
Free Cash Flow
-2,293.3%
More
EPS
$-2.7
FCF per Share
$-2.6
Short interest
15.1%
Employees
186
Rev per Employee
$40.0k
Show more

Is Celldex Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Celldex Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Celldex Therapeutics, Inc. forecast:

18x Buy
86%
3x Hold
14%

Analyst Opinions

21 Analysts have issued a Celldex Therapeutics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Celldex Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7.56 7.56
24% 24%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
21% 21%
533%
- Research and Development Expense 185 185
50% 50%
2,440%
-214 -214
34% 34%
-2,830%
- Depreciation and Amortization 3.27 3.27
7% 7%
43%
EBIT (Operating Income) EBIT -217 -217
34% 34%
-2,873%
Net Profit -179 -179
23% 23%
-2,366%

In millions USD.

Don't miss a Thing! We will send you all news about Celldex Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celldex Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
HAMPTON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2025 and provided a corporate update.
Neutral
GlobeNewsWire
about 2 months ago
HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating sym...
Neutral
GlobeNewsWire
2 months ago
HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by...
More Celldex Therapeutics, Inc. News

Company Profile

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Head office United States
CEO Anthony Marucci
Employees 186
Founded 1983
Website celldex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today